



Universiteit
Leiden
The Netherlands

Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients

Sénard, T.; Flouri, I.; Vuckovic, F.; Papadaki, G.; Goutakoli, P.; Banos, A.; ... ; Sidiropoulos, P.

Citation

Sénard, T., Flouri, I., Vuckovic, F., Papadaki, G., Goutakoli, P., Banos, A., ... Sidiropoulos, P. (2022). Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients. *Arthritis Research And Therapy*, 24(1). doi:10.1186/s13075-022-02897-5

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)
Downloaded from: <https://hdl.handle.net/1887/3731437>

Note: To cite this publication please use the final published version (if applicable).

RESEARCH

Open Access



Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients

Thomas Sénard¹, Irini Flouri², Frano Vučković³, Garyfalia Papadaki⁴, Panagiota Goutakoli⁴, Aggelos Banos⁵, Maja Pučić-Baković³, Marija Pezer³, George Bertias^{2,4}, Gordan Lauc^{3,6*} and Prodromos Sidiropoulos^{2,4}

Abstract

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease for which prediction of long-term prognosis from disease's outset is not clinically feasible. The importance of immunoglobulin G (IgG) and its Fc N-glycosylation in inflammation is well-known and studies described its relevance for several autoimmune diseases, including RA. Herein we assessed the association between IgG N-glycoforms and disease prognosis at 2 years in an early inflammatory arthritis cohort.

Methods: Sera from 118 patients with early inflammatory arthritis naïve to treatment sampled at baseline were used to obtain IgG Fc glycopeptides, which were then analyzed in a subclass-specific manner by liquid chromatography coupled to mass spectrometry (LC-MS). Patients were prospectively followed and a favorable prognosis at 2 years was assessed by a combined index as remission or low disease activity (DAS28 < 3.2) and normal functionality (HAQ ≤ 0.25) while on treatment with conventional synthetic DMARDs and never used biologic DMARDs.

Results: We observed a significant association between high levels of IgG2/3 Fc galactosylation (effect 0.627 and adjusted *p* value 0.036 for the fully galactosylated glycoform H5N4F1; effect -0.551 and adjusted *p* value 0.04963 for the agalactosylated H3N4F1) and favorable outcome after 2 years of treatment. The inclusion of IgG glycoprofiling in a multivariate analysis to predict the outcome (with HAQ, DAS28, RF, and ACPA included in the model) did not improve the prognostic performance of the model.

Conclusion: Pending confirmation of these findings in larger cohorts, IgG glycosylation levels could be used as a prognostic marker in early arthritis, to overcome the limitations of the current prognostic tools.

Keywords: Rheumatoid arthritis, Immunoglobulin G, Fragment crystallizable, N-glycosylation, Inflammation

Background

Rheumatoid arthritis (RA) is a common systemic autoimmune disease that causes primarily chronic joint inflammation and functional limitation [1]. Major steps in

understanding disease's pathogenesis have been accomplished, revealing several genetic loci, epigenetic mechanisms and environmental factors involved in breaching immune tolerance for disease initiation and progression [2]. Auto-immunity to post-translationally modified proteins [citrullinated (ACPAs), carbamylated (anti-CarP Abs)] as well as the development of rheumatoid factors (RFs) which recognize immunoglobulin G (IgG) Fc

*Correspondence: glauc@genos.hr

⁶ Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

fragments, start in the preclinical stage of the disease [3, 4]. Several mechanisms mostly unknown, contribute to the progression to clinically apparent synovitis, a stage when the patient firstly present to the clinic [5]. Physicians evaluating for the first time patients with inflammatory arthritis have to make a diagnosis and assess the prognosis. Diagnosis of RA is still mainly based on clinical data, while laboratory tests like RA-specific autoantibodies and acute-phase reactants, assist in the diagnosis [6]. Although autoantibodies (RFs and ACPAs) can be present years before the disease appears [7], they have limitations as diagnostic tools since healthy persons may also develop mostly RF, and recent epidemiological studies have shown an increased incidence (up to 50%) of RF and ACPA seronegative RA [8, 9]. Interestingly, patients not fulfilling the classification criteria for RA but having inflammatory arthritis and no evidence of another systemic autoimmune disease are classified as undifferentiated arthritis (UA) and treated accordingly [10]. The second challenge is to assess the prognosis of early RA patients. Most studies based on clinical, serological, and baseline radiological data, revealed that the presence of RF or ACPAs, presence of bone erosions, and increased acute phase reactants predict a more aggressive disease [11]. Nevertheless, the accuracy of the currently proposed models for predicting joint damage or response to therapy has limitations [12, 13]. Thus, there is a need for novel diagnostic and prognostic biomarkers. Along this concept, there are recent data supporting the value of high-throughput molecular data at the single-cell level as prognostic tools for disease's outcome [14, 15].

RF and ACPA of IgG isotype belong to the family of glycoproteins. Their fragment crystallizable (Fc)-region, as well as seldomly the antigen-binding (Fab)-regions, are known to be *N*-glycosylated. The *N*-glycosylation profile is essential for antibodies' effector and antigen binding functions and was shown to depend on different factors such as genetics, epigenetics, aging, and pathological states [16–18]. Studies of total serum IgG *N*-glycosylation from RA patients demonstrated a lower galactosylation, which was associated to disease activity, but also predicted the patients' response to therapy and preceded disease onset by up to several years [19–24]. Moreover, glycosylation of antigen-specific IgGs, such as ACPA, was shown to differ from total IgGs in both Fc and Fab regions, thus influencing its functional activities [25–27]. This stresses the importance of IgG glycosylation to RA pathogenesis. Interestingly, mouse studies have shown that IL-23-activated TH17 cells accumulating in germinal centers during the prodromal phase of experimental arthritis, can alter the glycosylation profile of IgGs toward a pro-inflammatory autoantibody repertoire and trigger the onset of experimental arthritis [28].

A previous small study from Lundström et al. revealed changes in IgG-Fc galactosylation in the early stage of RA as well as its possible predictive power on the treatment response [29].

In the current study, we evaluated the value of total serum IgG Fc *N*-glycosylation as a diagnostic and prognostic biomarker of patients with early arthritis. We applied a state-of-the-art liquid chromatography–mass spectrometry (LC-MS) based workflow for the analysis of subclass-specific IgG Fc *N*-glycosylation in the sera of 118 early, naïve to treatment, inflammatory arthritis patients. Patients were cross-sectionally sampled at baseline and prospectively followed for 2 years. A diagnosis of RA or UA was based on established classification criteria, while the long-term prognosis of the disease was assessed during 2 years of follow-up.

Methods

Materials

Formic acid (FA) was purchased from Merck (Darmstadt, Germany). Ammonium bicarbonate (ABC) was acquired from Acros Organics (Pittsburgh, PA, USA). Trifluoroacetic acid (TFA) was obtained from Sigma-Aldrich (St Louis, MI, USA). LC-MS grade acetonitrile (ACN) was purchased from Honeywell (Morris Plains, NJ, USA). Sequencing grade trypsin was obtained from Promega (Fitchburg, WI, USA).

Patients cohort—outcomes

The “Early Arthritis Clinic” of the University Hospital of Heraklion is a prospective cohort of patients with inflammatory arthritis and its details were previously described by Fanouriakis et al. [13]. Briefly, patients were assessed at baseline and in regular intervals up to 2 years. For the present study, we selected a group of patients naïve to any immunosuppressive treatments with available serum at baseline evaluation ($n=118$). At baseline, demographics, RA clinical characteristics [disease activity assessed by 28 joint counts (DAS28), functionality assessed by “Health Assessment Questionnaire (HAQ-DI)], and laboratory tests [autoantibodies (RF and/or ACPA)] were also recorded (Table 1). The patients were prospectively followed for 2 years, with clinical, laboratory, and disease-related treatments documented. Treatment decisions were made by treating rheumatologists, according to national guidelines, while no strict treat-to-target protocol was followed. The study was approved by the Institutional Review Board of the University Hospital of Heraklion, Crete (decision number: 1476/20-03-2012), and all patients provided written informed consent for their participation.

Concerning the outcomes for the present analysis, a diagnosis of RA or UA was done either at the baseline

Table 1 Baseline demographics, clinical characteristics, and patient treatments at the end of follow-up (24 months)

| Characteristics | RA and UA patients (n = 118) |
|-----------------------------------------------------------------------|------------------------------|
| Age (mean ± SD) | 53 ± 15.66 |
| Gender (% females) | 80.5 |
| Symptoms duration (weeks mean ± SEM) | 53.79±8.72 |
| RF positive (%), mean (SD) | 8.4, [35.6 (167.9)] |
| ACPA positive (%), mean (SD) | 16, [21.9 (50.8)] |
| ESR (mean ± SEM, mm/h) | 30.46 ± 2.36 |
| CRP (mean ± SEM, mg/dL) | 1.96 ± 0.35 |
| Disease activity score 28 joints (DAS28) (mean ± SEM) | 4.85 ± 0.14 |
| Treatments during 24 months of follow-up, N(% of all patients) | |
| Biologic DMARD +/- csDMARDs | 16 (13.6) |
| Methotrexate | 45 (38.1) |
| Leflunomide | 26 (22) |
| HCQ | 31 (26.3) |
| Corticosteroids per os | 11 (9.3) |

RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, HCQ hydroxychloroquine

evaluation or whenever during the follow-up, based on established criteria [6]. Moreover, aiming to assess long-term outcomes (at 2 years) and in order to overcome the limitation of missing data, we formulated 3 composite long-term outcomes of clinical significance (Table 2): (1) initiation of biological disease-modifying antirheumatic drug (bDMARD) at any time during follow-up (adverse outcome 1), (2) presence of high disease activity (HDA) (based on DAS28 > 5.1) or compromised function (based on HAQ > 1.0) at 2 years while on treatment with conventional synthetic DMARDs (csDMARDs) (except hydroxychloroquine (HCQ) or initiation of bDMARDs (adverse outcome 2), (3) remission or low disease activity (based on DAS28 < 3.2) and normal functionality (based on HAQ ≤ 0.25) while on treatment with csDMARDs and never use bDMARDs (favorable outcome).

Samples and in-house serum standards were randomized into two 96-well plates prior to IgG isolation.

IgG isolation

IgGs were captured from serum by affinity chromatography using 96-well protein G monolithic plate

(BIA Separations, Ajdovščina, Slovenia) as previously described by Pučić et al. [30]. Briefly, 100 µL of serum was diluted with 700 µL of 1X phosphate-buffered saline (PBS) and filtered through a 0.45µm GHP filter plate (Pall Corporation, Ann Arbor, MI, USA). Samples were then loaded onto a protein G plate and washed three times with 2 mL of 1X PBS. IgGs were eluted with 1 mL of 0.1 M FA and neutralized with 170 µL of 1 M ABC. The protein concentration was measured using a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).

IgG digestion and purification

After isolation, an aliquot of isolated IgGs (ranging from 7.44 to 46 µg) was digested with 0.18 µg of sequencing grade trypsin overnight at 37 °C. The tryptic digests were cleaned-up by reverse-phase solid-phase extraction (RP-SPE) using Chromabond C18 beads (Macherey-Nagel, Düren, Germany). In short, samples were diluted ten times with 0.1 % TFA, loaded onto beads, and then washed three times with 0.1 % TFA. Glycopeptides were

Table 2 Different outcomes assessed for the statistical analysis

| Outcomes | Conditions | Data availability |
|-----------|------------------------------------------------------------------------------|-------------------|
| Adverse 1 | Treatment with bDMARD within 2 years | 118/118 |
| Adverse 2 | HAQ > 1 or DAS28 > 5.1 while on csDMARDs or treatment with bDMARD at 2 years | 94/118 |
| Favorable | DAS28 < 3.2 and HAQ ≤ 0.25 and no treatment with bDMARD at 2 years | 93/118 |

eluted from the beads using 20 % ACN and dried down by vacuum centrifugation.

RPLC-MS analysis of IgG-Fc glycopeptides

The obtained glycopeptides were reconstituted in 20 μ L ultrapure water before being analyzed by reverse-phase liquid chromatography (RPLC) coupled with mass spectrometry (MS). LC separations were performed on a nanoAcquity UPLC system (Waters, Milford, MA, USA) coupled to a quadrupole time-of-flight (q-TOF) MS instrument (Compact, Bruker, Bremen, Germany) using a CaptiveSpray electrospray ionization (ESI) source from Bruker. Separations were carried out using a C18 analytical column (150 mm x 100 μ m ID, 100 Å , Advanced Materials Technology, Wilmington, DE, USA) and the column compartment was set to 30 °C. The samples (10 μ L) were loaded first on a C8 trap column (PepMap 100, 5 mm x 300 μ m ID, Thermo Fisher Scientific) at a flow rate of 15 μ L/min. The separations were achieved using mobile phases which consisted in 0.1 % TFA for solvent A and 80 % ACN, 0.1 % TFA for solvent B. The gradient was from 18 % to 28 % of solvent B in solvent A at a flow rate of 1 μ L/min for 8 min.

The mass spectrometer was operated in positive-ion mode with electrospray voltage set to 1.5 kV. The ESI source was used with a CaptiveSpray nanobooster to add a dopant enriched nitrogen in combination with ACN at a pressure of 0.2 bar as well as a drying gas of nitrogen set to 4 L/min at 150 °C. The quadrupole collision cell energy was 5 eV. Mass spectra were recorded in a m/z range of 800–2000.

LC-MS data were treated with a specific software (LacyTools version 1.1.0) as previously described [31] with minor changes such as the minimum features for alignment was set to 5 and the number of data points was 33. To compare measurements across samples and calculate the relative abundances of each IgG isoform, the following normalization method was performed. First, the isotopic pattern was corrected for each glycopeptide by summing the intensities at charge states 2+ and 3+ and dividing them by the fraction of the isotopic pattern found by the software. Then, the relative abundance of each glycopeptide was calculated by dividing the corrected sum by the total intensity of each peak. The relative abundance is expressed in % of total normalized intensity and represents the relative abundance of the given glycopeptide within the sum of all glycopeptides recorded for a single subclass. This treatment resulted in relative abundance data of 16 IgG1, 9 IgG2/3, which share the same tryptic peptide sequence, and 10 IgG4 Fc *N*-glycoforms available for each sample.

The robustness of the method was assessed by calculating the average relative abundances, the standard

deviations (SD) and the coefficients of variation (CV) from all the glycoforms of each IgG subclass of 7 serum standards. The median CVs were 3.74% for IgG1, 4.88% for IgG2/3, and 4.10% for IgG4 (Supplementary Table 1).

Statistical analysis

The results of subclass-specific IgG Fc *N*-glycoprofiling were then subjected to statistical analysis via a general linear model (ANCOVA) and corrected for age, sex, and duration of symptoms. Prior to analyses, glycan variables were all transformed to a standard normal distribution (mean = 0, SD = 1) by an inverse transformation of ranks to normality (R package “GenABEL,” function `rntransform`). Using rank-transformed variables in analyses makes estimated effects of different glycans comparable, as transformed glycan variables have the same standardized variance. False rate discovery was controlled using the Benjamini-Hochberg procedure. As IgGs showed different numbers of glycoforms per subclass and due to the smaller sample size which would make the multiple testing burden too large, only the 4 most abundant species were used in the statistical analysis. These species H3N4F1, H4N4F1, H5N4F1, and H5N4F1S1 can be described by their number of hexose (H), *N*-acetylglucosamine (N), fucose (F) and sialic acid residues (S). Patients were classified into 2 groups, based on their diagnosis, either rheumatoid arthritis (RA, group 1, 60% of patients) or undifferentiated arthritis (UA, group 2, 40% of patients). Three different long-term outcomes were tested, 2 adverse and 1 favorable based on the clinical traits after 2 years (Table 2).

Results

Lack of association of IgG glycosylation profiles to diagnosis

LC-MS-based workflow was used to study subclass-specific IgG Fc *N*-glycosylation in 118 early inflammatory arthritis patients sampled before any treatment. LC conditions resulted in the separation of the glycopeptides from IgG1 (EEQYNSTYR), IgG2/3 (EEQFNSTFR), and IgG4 (EEQFNSTYR) (shown in Supplementary Fig. 1). Relative abundances of all glycoforms were obtained from the LC-MS data (Supplementary Fig. 2) before being treated with the LaCyTools software. The statistical analysis was performed using the relative abundances of the four most abundant glycoforms of IgG1, 2/3, and 4.

At first, we looked at the differences in the relative abundances of the 4 most abundant glycoforms (H3N4F1, H4N4F1, H5N4F1, and H5N4F1S1) between the 2 diagnostic groups, namely RA and UA (Fig. 1). Even though patients diagnosed with early undifferentiated arthritis (group 2) had higher relative abundances of galactosylated and sialylated *N*-glycoforms (H4N4F1,

H5N4F1, and H5N4F1S1) in all IgG subclasses compared to rheumatoid arthritis patients (group 1), none of the differences reached significance threshold (Supplementary Table 2).

IgG glycosylation profile predicts long-term outcome

Since the two diagnosis groups showed no statistically significant differences in glycosylation profiles, they were grouped together for further analysis of the association between IgG *N*-glycoforms and disease outcomes defined in three different groups (adverse outcomes 1 and 2, and favorable outcome; Table 2). The analysis revealed a significant association between IgG2/3 Fc *N*-glycoforms describing galactosylation levels (H3N4F1 and H5N4F1) and “favorable outcome” (defined as DAS28 < 3.2 and HAQ ≤ 0.25 and no treatment with bDMARD at 2 years) (Supplementary Table 3). Patients with a higher pre-treatment galactosylation (higher abundance of H5N4F1) and hence a lower pre-treatment agalactosylation of IgG2/3 (lower abundance of H3N4F1) showed a favorable outcome after 2 years of treatment (Fig. 2). Sialylation of the same subclass (IgG2/3 H5N1F1S1) as well as galactosylation and sialylation of both IgG1 and IgG4 seemed to follow the same trend but the adjusted *p*-values were not significant (Supplementary Table 3). Interestingly, when we analyzed baseline glycosylation levels with individual parameters (i.e., DAS28 at 24 months, HAQ at 24 months, use of biologics ever) we found no statistical association, apart from a trend of association between IgG1 (H5N4F1S1) and HAQ difference between baseline and 24 months (*p* adj=0.087).

Next, we checked for associations between clinical traits at baseline, such as seropositivity (i.e., the presence of RF and/or anti-CCP antibodies), DAS28 (low < 3.2 versus medium-high ≥ 3.2) HAQ (mild-moderate compromised function < 1 versus severe disability ≥ 1), and the outcomes after 2 years. While HAQ was associated with “adverse outcomes 1” and “2”, DAS28 was associated with “favorable outcome” (Supplementary Table 4). The correlation between the glycoforms of IgG subclasses and the baseline clinical traits, acute phase reactants, and autoantibody levels (RF and ACPA levels) was also tested but did not show any statistically significant associations (Supplementary Table 5). Finally, in a multivariate analysis to predict outcome (with HAQ, DAS28, RF, and

ACPA included in the model), the inclusion of IgG glyco-profiling did not improve the prognostic performance of the model (data not shown).

Discussion

In the present study, we applied a validated and high-throughput subclass-specific IgG Fc *N*-glycosylation LC-MS profiling method, to evaluate IgG glycosylation status as a diagnostic and prognostic tool in early inflammatory arthritis patients [32]. Moreover, with regard to sample processing and data analysis, this method has also been optimized to minimize the batch effect as well as other effects that can occur during the analysis of a large number of samples. This state-of-the-art method has been widely recognized as a powerful diagnostic tool for the analysis of IgG glycosylation [33, 34]. Thus, after quantification of several glycoforms, corrected for baseline factors which may affect IgG glycosylation (symptoms duration, age, and sex) we found glycosylation profiles to be associated with 2 years’ prognosis [30, 35]. Of note, the serum samples used in this study were derived from treatment-naïve patients; therefore, variations in IgG glycosylation do not represent any therapeutic effect but may reflect the impact of inflammation.

Approximately 50–70% of the patients with early arthritis progress to RA, while 30–40% have a diagnosis of UA [36]. Thus, the first clinical challenge when assessing patients with early inflammatory arthritis is to establish the diagnosis. For this reason, we aimed to assess the correlation between IgG *N*-glycosylation and the two diagnostic groups. Preliminary statistical analysis did not reveal significant differences in IgG glycosylation between patients with UA and RA. This was not an unexpected finding since there are data supporting a decreased immunoglobulins’ glycosylation profile in inflammatory arthritides, irrespective of the specific diagnosis (RA or spondylarthritis). Moreover, although data comparing levels of glycosylation between different arthritides are not available, it has been shown that effective treatment with TNF inhibitors increased IgG glycosylation levels in both RA and spondylarthritis [37]. Consequently, our data corroborate the above-mentioned data supporting that glycosylation levels are mostly affected by the inflammatory burden and that disease-specific mechanisms are not important contributors.

(See figure on next page.)

Fig. 1 Relative abundances of subclass-specific IgG Fc *N*-glycoforms (H3N4F1, H4N4F1, H5N4F1, H5N4F1S1) in two diagnosis groups: 1 – rheumatoid arthritis; 2 – undifferentiated arthritis. No statistically significant differences between the groups using a general linear model as specified in the Methods section. Glycan compositions are given in terms of Hexose (H), *N*-acetylglucosamine (N), fucose (F), and sialic acid residues (S). The data were presented as a box plot where the lower and upper hinges correspond to the first and third quartiles. The upper whisker extends from the hinge to the largest value no further than 1.5 times the inter-quartile range (IQR) from the hinge while the lower one extends to the smallest value at most 1.5 times IQR. Data beyond the end of the whiskers are outliers and are plotted individually. The value represents the relative abundance of each presented glycoform within the sum of all glycoforms on a single subclass




Fig. 1 (See legend on previous page.)

As previously mentioned, for patients with early inflammatory arthritis—either RA or UA—the second challenge is to predict the long-term prognosis. To address this, we set up 3 major outcomes of clinical importance based on disease activity/function at 24 months and medication used during the 2-year period. We used a combination of clinically significant parameters, since the use of biologics was rather low (16.9% (20/118)) and, most importantly, in clinical practice treatment decisions are not strictly based on disease activity levels for various reasons (both patient- and physician-related) [38–40]. Thus, as it has been shown in several early arthritis cohorts, 35–55% of early arthritis patients are not treated with bDMARDs according to the treat-to-target principle, we considered it valid to have a “combo” outcome including treatment with bDMARDs and high disease activity/compromised function. The analysis showed that, by keeping the two diagnostic groups separated, there were no statistically significant associations between IgG glycoforms and neither adverse nor favorable outcomes. Nevertheless, by combining these two groups together, and thus increasing the statistical power, a significant association was shown between higher levels of digalactosylated IgG glycoforms and favorable outcomes after 2 years of treatment. These results are in line with previous studies as aberrant IgG *N*-glycosylation profile in RA patients has been reported multiple times [22–24]. Lower level of IgG galactosylation was shown to associate with disease activity and symptom severity and even preceded the development of disease [17, 41]. Nonetheless, our study is the first to show an association of IgGs glycosylation profile and long-term outcome. The small number of patients in our study could explain why only the IgG2/3 subclasses express this typical agalactosylation level, as we would expect the same trend for IgG1. Other possible reason could be subtle differences in Fc glycosylation profiles of different IgG subclasses. Thus, we find lower galactosylation and sialylation of IgG2/3 compared to other subclasses, confirming observations from previous studies [42, 43]. These differences in Fc glycosylation reflect in their binding affinity towards Fcγ-receptors (FcγR) and ability to modulate effector functions [44]. According to literature, IgG2 has the lowest affinity for FcγRs and lowest ADCC capacity, while the opposite is true for IgG3 [44–46]. Unfortunately, the used glycoprofiling method did not allow separate identification of IgG2 and IgG3 Fc glycoforms thus hampering the

evaluation of their distinct associations with the disease outcome.

Interestingly, in our cohort once again the value of a patient’s functionality (HAQ status) was associated with long-term prognosis. Nevertheless, in the multivariate analysis, glycosylation status was not predictive of the 2 years’ outcome.

A limitation of our study is that we have not had the possibility to assess the biological significance of IgG glycosylation alterations in the context of an autoimmune disease. This is especially true for autoantibodies positive (ACPA or RF) RA. Nevertheless, published literature suggests potential mechanisms of IgG-Fc glycosylation levels contribute to immune responses. Thus, it has been shown that the two Fc-linked carbohydrates interposed between the heavy chains are crucial for the three-dimensional structure and biological activity of the antibody [47]. Data have shown that the removal of the Fc glycans diminishes IgG Fc-mediated biological activity due to the failure of the non-glycosylated molecule to bind to FcγR [48]. Additionally, certain modifications affect IgG-mediated antibody-dependent cellular cytotoxicity (ADCC) [49], while Fc-linked glycans modulate the activation of the complement cascade [50]. Finally, it has been shown that highly galactosylated IgG1 immune complexes (ICs), the inhibitory IgG receptor Fc-gamma RIIB and the C-type lectin-like receptor dectin-1, suppress C5a receptor (C5aR) functions and respective C5a-dependent inflammatory responses [51]. Whether the above mechanisms are important in the context of RA or whether they affect the function of RA-specific autoantibodies is not yet addressed. Notably, and corroborating the possibility of contribution in the inflammatory responses in RA, it has been observed a significant correlation between levels of aberrant IgG galactosylation and disease activity in RA patients [52].

An additional limitation of our study is the lack of sequential sampling of the patients during follow-up. One could argue that this supplementary information could have additive value to the baseline characteristics of IgG *N*-glycosylation status, as a predictor for disease’s outcome. Nevertheless, the analysis would have been more complicated since the potential contribution of other factors while on treatment (infections, aging, treatment effect, etc.), cannot be excluded. Indeed, alterations with total (not antigen-specific) IgG glycosylation have been associated with various physiological and

(See figure on next page.)

Fig. 2 Relative abundances of subclass-specific IgG Fc *N*-glycoforms (H3N4F1, H4N4F1, H5N4F1, H5N4F1S1) in patients without (0) or with (1) “Favorable outcome” after 2 years of treatment. “Favorable outcome” was defined as DAS28 < 3.2, HAQ ≤ 0.25, and no biological disease-modifying antirheumatic drug was received during treatment. *Statistically significant associations (adjusted *p* value < 0.05) following the general linear model described in the Methods section. Glycan compositions and box plot description as in Fig. 1




Fig. 2 (See legend on previous page.)

pathological states since they seem responsive to general inflammatory capacity.

Conclusion

In conclusion, we found IgG2/3 Fc *N*-glycoforms to be associated with a favorable prognosis (low disease activity or remission, preserved functionality, and no treatment with bDMARD) in patients with early arthritis follow-up for 2 years. Should the present data be confirmed in a larger cohort could be of clinical value. Since currently available prognostic tools have significant limitations, further research should aim to develop a predictive tool of high specificity and sensitivity based on the combination of clinical, serological data and novel biomarkers.

Abbreviations

ABC: Ammonium bicarbonate; ACN: Acetonitrile; ACPA: Anti-citrullinated peptides antibodies; bDMARD: Biological disease-modifying antirheumatic drug; CCP: Cyclic citrullinated peptides; csDMARD: Conventional synthetic disease-modifying antirheumatic drug; CV: Coefficient of variation; DAS28: Disease activity score; ESI: Electrospray ionization; Fab: Fragment antigen-binding; Fc: Fragment crystallizable; FA: Formic acid; HAD: High disease activity; HAQ: Health assessment questionnaire; HCQ: Hydroxychloroquine; IgG: Immunoglobulin G; LC-MS: Liquid chromatography–mass spectrometry; PBS: Phosphate-buffered saline; RA: Rheumatoid arthritis; RF: Rheumatoid factor; SD: Standard deviation; TFA: Trifluoroacetic acid; UA: Undifferentiated arthritis.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13075-022-02897-5>.

Additional file 1: Supplementary Figure 1. Example of IgG glycopeptides subclass separation of the H4N4F1 *N*-glycoform. Extracted-ion chromatogram (EIC) of IgG1 (EEQYNSTYR) is represented by the red trace, IgG2/3 (EEQFNSTFR) by the blue trace and IgG4 (EEQFNSTYR) by the green trace. LC-MS conditions: Temperature 30°C. Gradient from 18% to 28% B in 8 min at 1 µL/min. H4N4F1 glycoform is represented using the Symbol Nomenclature for Glycans.

Additional file 2: Supplementary Figure 2. Example of MS spectra with their annotated glycoforms for IgG1 (A), IgG2/3 (B) and IgG4 (C). The right side of each panel represents the glycoforms at the charge state +2 while the left side shows the same glycoforms at the charge state +3. The individual glycoforms are represented using the Symbol Nomenclature for Glycans.

Additional file 3: Supplementary Table 1. Average relative abundances, standard deviations (SD), coefficients of variation (CV) and median CVs of IgG *N*-glycoforms, from the 7 serum standards, quantified with the LaCy-Tools software. Relative abundances were calculated following normalization of total intensity as described in the Methods section.

Additional file 4: Supplementary Table 2. Association of relative abundances of IgG *N*-glycoforms and the two diagnosis groups. Standard errors, *p*-values and *p*-values adjusted for multiple testing (*p*-value adjusted > 0.05) were calculated following the general linear model with age, sex and duration of symptoms included as additional covariates.

Additional file 5: Supplementary Table 3. Association of the relative abundances of IgG *N*-glycoforms of the two diagnosis groups and the different clinical outcomes ("favorable outcome" and "adverse outcomes 1" and "2"). Standard errors, *p*-values and *p*-values adjusted for multiple testing were calculated based on the general linear model with age, sex and duration of symptoms included as additional covariates. Statistically significant associations are described by an adjusted *p*-value < 0.05.

Additional file 6: Supplementary Table 4. Association of baseline clinical characteristics and long-term outcomes. Standard errors, *p*-values and *p*-values adjusted for multiple testing were determined using a general linear model (age, sex and duration of symptoms included as additional covariates) and based on HAQ, DAS28, seropositivity (presence of RF and/or anti-CCP antibodies) at baseline of the two diagnosis groups for the "favorable outcome" and "adverse outcomes 1" and "2". Statistically significant associations are described by an adjusted *p*-value < 0.05.

Additional file 7: Supplementary Table 5. Association of IgG *N*-glycoforms and baseline clinical characteristics (HAQ, DAS28, seropositivity, acute phase reactants and autoantibody levels) of the two diagnostic groups. Standard errors, *p*-values and *p*-values adjusted for multiple testing were calculated following a general linear model (age, sex and duration of symptoms included as additional covariates) and based on the relative abundance of IgG *N*-glycoforms (*p*-value adjusted > 0.05).

Acknowledgements

None

Authors' contributions

P.S., M.P., and G.L. designed the study. A.B., P.G., and G.P. acquired the serum samples. T.S. and M.P.-B. performed the glycopeptides analysis. F.V. carried out the statistical analysis. F.V., T.S., M.P.-B., M.P., and I.F. interpreted the data. T.S. wrote the original draft of the manuscript. M.P.-B., M.P., F.V., P.S., and G.B. reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the GlySign and SYSCID – European Union's Horizon 2020 research and innovation programs under the Marie Skłodowska-Curie, grant numbers 722095 and 733100, respectively.

Availability of data and materials

Raw data supporting the research of this article will be made available by the authors, without undue reservation.

Declarations

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of the University Hospital of Heraklion, Crete (decision number: 1476/20-03-2012), and all patients provided written informed consent for their participation.

Consent for publication

Not applicable.

Competing interests

G.L. is the founder and owner of Genos Ltd, a private research organization that specializes in high-throughput glycomic analyses and has several patents in this field. F.V., M.P.-B., and M.P. are employees of Genos Ltd. All other authors declare no conflict of interest.

Author details

¹Center for Proteomics and Metabolomics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. ²Rheumatology and Clinical Immunology, University Hospital of Heraklion, 71003 Heraklion, Greece. ³Genos Glycoscience Research Laboratory, Zagreb, Croatia. ⁴Laboratory of Rheumatology, Autoimmunity and Inflammation, Medical School, University of Crete, 71305 Heraklion, Greece. ⁵Laboratory of Inflammation and Autoimmunity, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece. ⁶Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.

Received: 24 February 2022 Accepted: 24 July 2022

Published online: 25 August 2022

References

- Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. *Lancet*. 2016;388(10055):2023–38.
- Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. *Immunity*. 2017;46(2):183–96.
- Ligier S, Fortin PR, Newkirk MM. A new antibody in rheumatoid arthritis targeting glycosylated IgG: IgM anti-IgG-AGE. *Br J Rheumatol*. 1998;37(12):1307–14.
- van Delft MAM, Huizinga TWJ. An overview of autoantibodies in rheumatoid arthritis. *J Autoimmun*. 2020;110:102392.
- Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. *Nat Immunol*. 2021;22(1):10–8.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis*. 2010;69(9):1580–8.
- Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. *Lancet*. 2010;376(9746):1094–108.
- van Zanten A, Arends S, Rozenendaal C, Limburg PC, Maas F, Trouw LA, et al. Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. *Ann Rheum Dis*. 2017;76(7):1184–90.
- Myasoedova E, Davis J, Matteson EL, Crowson CS. Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. *Ann Rheum Dis*. 2020;79(4):440–4.
- Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Alvaro-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. *Ann Rheum Dis*. 2017;76(6):948–59.
- Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. *Arthritis Rheum*. 2001;44(8):1736–43.
- Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, et al. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. *Health Technol Assess*. 2018;22(66):1–294.
- Fanouriakakis A, Papalopoulos I, Gergianaki I, Spyrou G, Erden A, Rapsomaniki P, et al. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study. *Clin Exp Rheumatol*. 2018;36(5):806–13.
- Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, et al. Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. *Cell Rep*. 2019;28(9):2455–70 e5.
- Lliso-Ribera G, Humby F, Lewis M, Nerviani A, Mauro D, Rivellesse F, et al. Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). *Ann Rheum Dis*. 2019;78(12):1642–52.
- Menni C, Keser T, Mangino M, Bell JT, Erte I, Akmacic I, et al. Glycosylation of immunoglobulin G: role of genetic and epigenetic influences. *PLoS One*. 2013;8(12):e82558.
- Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. *Cell Immunol*. 2018;333:65–79.
- Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. *Nat Rev Nephrol*. 2019;15(6):346–66.
- Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. *Nature*. 1985;316(6027):452–7.
- Gudelj I, Salo PP, Trbojevic-Akmacic I, Albers M, Primorac D, Perola M, et al. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. *Biochim Biophys Acta Mol Basis Dis*. 2018;1864(6 Pt A):2034–9.
- Dekkers G, Rispen T, Vidarsson G. Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases. *Front Immunol*. 2018;9:553.
- Bodman-Smith K, Sumar N, Sinclair H, Roitt I, Isenberg D, Young A. Agalactosyl IgG [Gal(o)]--an analysis of its clinical utility in the long-term follow-up of patients with rheumatoid arthritis. *Br J Rheumatol*. 1996;35(11):1063–6.
- Gindzienska-Sieskiewicz E, Klimiuk PA, Kisiel DG, Gindzienski A, Sierakowski S. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. *Clin Rheumatol*. 2007;26(5):685–90.
- van Zeben D, Rook GA, Hazes JM, Zwinderman AH, Zhang Y, Ghelani S, et al. Early agalactosylation of IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: results of a follow-up study. *Br J Rheumatol*. 1994;33(1):36–43.
- Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. *Ann Rheum Dis*. 2015;74(1):234–41.
- Rombouts Y, Willemze A, van Beers JJ, Shi J, Kerkman PF, van Toorn L, et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. *Ann Rheum Dis*. 2016;75(3):578–85.
- Scherer HU, van der Woude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA, Wang J, et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. *Arthritis Rheum*. 2010;62(6):1620–9.
- Pfeifle R, Rothe T, Ipseiz N, Scherer HU, Culemann S, Harre U, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. *Nat Immunol*. 2017;18(1):104–13.
- Lundstrom SL, Hensvold AH, Rutishauser D, Klareskog L, Ytterberg AJ, Zubarev RA, et al. IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis. *Arthritis Res Ther*. 2017;19(1):182.
- Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. *Mol Cell Proteomics*. 2011;10(10):M111 010090.
- Jansen BC, Falck D, de Haan N, Hipgrave Ederveen AL, Razdorov G, Lauc G, et al. LaCyTools: A Targeted Liquid Chromatography-Mass Spectrometry Data Processing Package for Relative Quantitation of Glycopeptides. *J Proteome Res*. 2016;15(7):2198–210.
- De Leoz MLA, Duewer DL, Fung A, Liu L, Yau HK, Potter O, et al. NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods. *Mol Cell Proteomics*. 2020;19(1):11–30.
- Simurina M, de Haan N, Vuckovic F, Kennedy NA, Stambuk J, Falck D, et al. Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. *Gastroenterology*. 2018;154(5):1320.
- Peng J, Vongpatanasin W, Sacharidou A, Kifer D, Yuhanna IS, Banerjee S, et al. Supplementation With the Sialic Acid Precursor N-Acetyl-D-Mannosamine Breaks the Link Between Obesity and Hypertension. *Circulation*. 2019;140(24):2005–18.
- Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. *J Exp Med*. 1988;167(5):1731–6.
- Hua C, Daien CI, Combe B, Landewe R. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. *RMD Open*. 2017;3(1):e000406.
- Collins ES, Galligan MC, Saldova R, Adamczyk B, Abrahams JL, Campbell MP, et al. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. *Rheumatology (Oxford)*. 2013;52(9):1572–82.
- Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. *Ann Rheum Dis*. 2012;71(6):845–50.
- Gavigan K, Nowell WB, Serna MS, Stark JL, Yassine M, Curtis JR. Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry. *Arthritis Res Ther*. 2020;22(1):4.
- Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, et al. Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. *Arthritis Res Ther*. 2015;17:48.
- Seeling M, Bruckner C, Nimmerjahn F. Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity? *Nat Rev Rheumatol*. 2017;13(10):621–30.

42. Bakovic MP, Selman MH, Hoffmann M, Rudan I, Campbell H, Deelder AM, et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. *J Proteome Res.* 2013;12(2):821–31.
43. Plomp R, Ruhaak LR, Uh HW, Reiding KR, Selman M, Houwing-Duistermaat JJ, et al. Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. *Sci Rep.* 2017;7(1):12325.
44. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. *Front Immunol.* 2014;5:520.
45. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. *Blood.* 2009;113(16):3716–25.
46. de Taeye SW, Bentlage AEH, Mebius MM, Meesters JI, Lissenberg-Thunnissen S, Falck D, et al. FcγRIIIB Binding and ADCC Activity of Human IgG Allotypes. *Front Immunol.* 2020;11:740.
47. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. *J Mol Biol.* 2003;325(5):979–89.
48. Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, et al. Aglycosylated IgG variants expressed in bacteria that selectively bind Fc γRI potentiate tumor cell killing by monocyte-dendritic cells. *P Natl Acad Sci USA.* 2010;107(2):604–9.
49. Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc γRIII and antibodies lacking core fucose. *P Natl Acad Sci USA.* 2011;108(31):12669–74.
50. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation Changes of IgG Associated with Rheumatoid-Arthritis Can Activate Complement Via the Mannose-Binding Protein. *Nat Med.* 1995;1(3):237–43.
51. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc γRIIIB and dectin-1. *Nat Med.* 2012;18(9):1401.
52. Ercan A, Cui J, Chatterton DEW, Deane KD, Hazen MM, Brintnell W, et al. Aberrant IgG Galactosylation Precedes Disease Onset, Correlates With Disease Activity, and Is Prevalent in Autoantibodies in Rheumatoid Arthritis. *Arthritis Rheum Us.* 2010;62(8):2239–48.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

